To register for the presentation, please contact your UBS consultant.
About Epygenix Therapeutics, Inc.
Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical firm centered on genetically screening, discovering, and creating medication to deal with uncommon and intractable types of genetic epilepsy in childhood, reminiscent of Dravet Syndrome. Epygenix is presently centered on creating EPX-100, EPX-200, and EPX-300. These drug candidates scale back convulsive habits and electrographic seizure exercise and have been found in a zebrafish Dravet Syndrome mannequin which replicates the genetic mutation and mimics the human pathology.
Epygenix’s largest shareholder is Mstone Partners, an entrepreneurial biotech incubator within the type of a holding firm which owns and manages a portfolio of drug growth firms. Mstone focuses on uncommon, pediatric, and neurodegenerative issues and progressive therapies for focused indications. Since 2016, Mstone has invested in two firms within the US and one in Hong Kong which are actually in superior clinical-stages with US FDA. Mstone has additionally established numerous portfolio firms beneath the Curestone Platform, which manages a portfolio of drug growth firms in a centralized, hub-and-spoke mannequin.
For extra data, please go to www.epygenix.com.
Andrew O
Epygenix Therapeutics
[email protected]